Linked Life Data

19034323

Source:http://linkedlifedata.com/resource/pubmed/id/19034323

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
111
pubmed:dateCreated
2008-11-28
pubmed:abstractText
Erythropoiesis stimulating agents (ESAs) are the main tool to achieve anemia correction in CKD patients. At present six different ESAs are available: epoetin alpha, epoetin beta, epoetin omega, epoetin delta, darbepoetin alpha, and very recently CERA. From one side the patent of older ESAs have expired, and biosimilars (for the moment only of epoetin alpha) have been approved for use in Europe by the European Medicines Agency. However, a number of issues about bioequivalence and how to test it are still to be solved completely. In the mean time pharmaceutical research has kept on working, developing new ESAs and alternative strategies for stimulating erythropoiesis. In this review we present and discuss these points.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0098-6577
pubmed:author
pubmed:issnType
Print
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S33-7
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Optimizing the management of renal anemia: challenges and new opportunities.
pubmed:affiliation
Department of Nephrology, Dialysis and Renal Transplant, Ospedale A. Manzoni, Lecco, Italy. nefrologia@ospedale.lecco.it
pubmed:publicationType
Journal Article, Review